Denali Therapeutics

failure crash no fail rocket cancelled end
Biotech

Sanofi flunks MS study, dealing another blow to Denali pact

Sanofi tore the RIPK1 inhibitor trial from its list of active studies after failing to meet its primary and secondary endpoints.
Nick Paul Taylor Oct 11, 2024 5:56am
Pathological phosphorylation yellow of Tau proteins red-orange by kinases violett leads to disintegration of microtubul

Researchers receive $6.9M NIA grant for tau-targeting drug

Aug 21, 2024 1:02pm
3d render of brain surrounded by pills

Denali reports new method to get ASOs across blood-brain barrier

Aug 14, 2024 2:00pm
door exit shut close end walk away

Biogen walks away from Denali Alzheimer's collab

Aug 1, 2024 10:27am
rare diseases

FDA picks Denali, Neurogene and more for rare disease program

Jun 4, 2024 2:51pm
packing boxes moving layoffs failure shut down

Amid pivot, Denali Therapeutics sends staff packing

Feb 26, 2024 12:22pm